5-AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK AML AND MDS

被引：0
|
作者：
Puglisi, Bruna
Saraceni, Francesco
Guerzoni, Selene
Scortechini, Ilaria
Mancini, Giorgia
Fiorentini, Alessandro
Lotito, Antonio
Colaneri, Francesca Romana
Federici, Irene
Olivieri, Attilio
机构：
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P307
引用
收藏
页码：364 / 365
页数：2
相关论文
共 50 条
  • [1] Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML
    El Chaer, Firas
    Borate, Uma
    Dulery, Remy
    Holtan, Shernan G.
    Law, Arjun Datt
    Muffly, Lori
    Nassereddine, Samah
    Shallis, Rory M.
    Stringaris, Kate
    Taylor, Justin
    Devine, Steven M.
    Mohty, Mohamad
    Hourigan, Christopher S.
    BLOOD ADVANCES, 2021, 5 (06) : 1757 - 1759
  • [2] 5-azacitidine is a possible therapeutic option for patients with relapsed AML or MDS after allogeneic stem cell transplantation
    Steckel, N. K.
    Gromke, T.
    Hegerfeldt, Y.
    Hlinka, M.
    Koldehoff, M.
    Ditschkowski, M.
    Elmaagacli, A.
    Beelen, D. W.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S540 - S541
  • [3] A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
    Oran, Betul
    de Lima, Marcos
    Garcia-Manero, Guillermo
    Thall, Peter F.
    Lin, Ruitao
    Popat, Uday
    Alousi, Amin M.
    Hosing, Chitra
    Giralt, Sergio
    Rondon, Gabriela
    Woodworth, Glenda
    Champlin, Richard E.
    BLOOD ADVANCES, 2020, 4 (21) : 5580 - 5588
  • [4] A dose and schedule finding study of maintenance therapy with low-dose 5-azacitidine (AZA) after allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk AML or MDS
    de Lima, Marcos
    Padua, L.
    Giralt, S.
    Hosini, C.
    Komanduri, K.
    Qazilbash, M.
    Shpall, E. J.
    Thall, P.
    Qureshi, S.
    McCormick, G.
    Tong, W.
    Popat, U.
    Soriano, A.
    Champlin, R.
    Garcia-Manero, G.
    BLOOD, 2007, 110 (11) : 884A - 885A
  • [5] 5-azacitidine in combination with donor lymphocyte infusions for the treatment of patients with MDS or AML relapsing after allogeneic stem cell transplantation
    Czibere, A.
    Graef, T.
    Bruns, I.
    Zohren, F.
    Germing, U.
    Haas, R.
    Kobbe, G.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S64 - S64
  • [6] 5-azacitidine in combination with donor lymphocyte infusions for the treatment of patients with MDS or AML relapsing after allogeneic stem cell transplantation.
    Czibere, Akos
    Graef, Thorsten
    Lind, Jens
    Gattermann, Norbert
    Zohren, Fabian
    Fenk, Roland
    Haas, Rainer
    Kobbe, Guido
    BLOOD, 2006, 108 (11) : 428B - 428B
  • [7] Allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) after pretransplant 5-azacitidine
    Field, Teresa
    Alsina, Melissa
    Ayala, Ernesto
    Fernandez, Hugo
    Janssen, William
    Karfan-Dabaja, Mohammed
    Lancer, Jeffery
    Melchert, Mafda
    Raychaudhuri, Jyoti
    Sullivan, Daniel
    List, Alan
    Anasetti, Claudio
    Poling, William
    Perkins, Janelle
    BLOOD, 2007, 110 (11) : 338B - 338B
  • [8] Efficacy of 5-azacitidine in treating imminent relapse of patients with high-risk MDS or AML and minimal residual disease after allogeneic stem cell transplantation: results of the RELAZA trial
    Platzbecker, U.
    Wermke, M.
    Radke, J.
    Kiani, A.
    Seltmann, F.
    Oelschlaegel, U.
    Roellig, C.
    Mohr, B.
    von Bonin, M.
    Schetelig, J.
    Ehninger, G.
    Bornhaeuser, M.
    Thiede, C.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S79 - S79
  • [9] HIGH TOLERABILITY OF PROLONGED AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML LACKING A TARGETABLE MUTATION
    Do, Cuong An
    Mamez, Anne-Claire
    Pradier, Amandine
    Morin, Sarah
    Bernardi, Chiara
    Prati-Perdikis, Sarah
    Beauverd, Yan
    Longval, Thomas
    Mappoura, Maria
    Noetzlin, Sarah
    Dubouchet, Laetitia
    Laspa, Evgenia
    Maulini, Marie
    Tran, Thien-An
    Ortiz, Carmen de Ramon
    Masouridi-Levrat, Stavroula
    Simonetta, Federico
    Chalandon, Yves
    Giannotti, Federica
    BONE MARROW TRANSPLANTATION, 2024, 59 : 163 - 164
  • [10] Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
    Garcia, Jacqueline S.
    Kim, Haesook T.
    Murdock, H. Moses
    Ansuinelli, Michela
    Brock, Jennifer
    Cutler, Corey S.
    Gooptu, Mahasweta
    Ho, Vincent T.
    Koreth, John
    Nikiforow, Sarah
    Romee, Rizwan
    Shapiro, Roman
    Deangelo, Daniel J.
    Stone, Richard M.
    Bat-Erdene, Denbaa
    Ryan, Jeremy
    Contreras, Manuel E.
    Fell, Geoffrey
    Letai, Anthony
    Ritz, Jerome
    Lindsley, R. Coleman
    Soiffer, Robert J.
    Antin, Joseph H.
    BLOOD ADVANCES, 2024, 8 (04) : 978 - 990
12345